ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had…
A new review highlighted JAK inhibitors’ role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.
This recap of skin cancer innovations accompanies the cover story of our May publication.
A 69-year-old man with a history notable for nonmelanoma skin cancer and being a nonsmoker sought dermatologic evaluation for a persistent, nonhealing lesion on his…
A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.
by Jacob Beer, MD; Sarah Hermak, MS; and Omar Noor, MD, FAAD Dr. Beer and Ms. Hermak are with the Dr. Phillip Frost Department of…
HMP Global launched a MATE Training Site to help prescribers earn their newly required CME credits. The M edication A ccess and T raining E…
This cohort study examines the association between methotrexate use and interstitial lung disease in patients with dermatomyositis.
My inspiration to pursue dermatology begins with my mother, the late Mercy Alexis Akuffo, who was the first Black female dermatologis…
INTRODUCTION The shape, projection, and profile of the chin are important components of facial attractiveness in both men and women. Chin retrusion may be perceived…